Item 5.02. Departure of Directors or Certain Officers; Election of Directors;


           Appointment of Certain Officers; Compensatory Arrangements of Certain
           Officers.


On May 5, 2022, we announced that Jim Hollingshead resigned as our president - sleep and respiratory care business, effective as of May 5, 2022, to pursue an opportunity with a new employer. In connection with his resignation, Robert ("Rob") Douglas, our president and chief operating officer, has been appointed to serve as our interim president - sleep and respiratory care business. We intend to commence a search for a permanent president - sleep and respiratory care business. A copy of the press release is furnished as Exhibit 99.1 to this current report on Form 8-K.

Mr. Douglas was appointed ResMed Inc.'s president in March 2013 and chief operating officer in September 2011; together with ResMed's chief executive officer, Michael ("Mick") Farrell, he holds full operational responsibility for ResMed and its subsidiaries.

There are no family relationships between Mr. Douglas and any director or executive officer of ResMed that are required to be disclosed under Item 401(d) of Regulation S-K, and there are no transactions between ResMed and Mr. Douglas that would require disclosure under Item 404(a) of Regulation S-K. The information concerning Mr. Douglas required under Item 401 of Regulation S-K is contained in ResMed's proxy statement dated October 6, 2021 and is incorporated here by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.



99.1      Press release issued by ResMed Inc. on May 5, 2022.

104     Cover Page Interactive Data File (embedded within the Inline XBRL, document)



                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses